

# Chronic inflammatory demyelinating polyneuropathy (CIDP) - Pipeline Insight, 2021

<https://marketpublishers.com/r/C77D069696CEN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: C77D069696CEN

## Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Chronic inflammatory demyelinating polyneuropathy (CIDP) - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

## Geography Covered

Global coverage

Chronic inflammatory demyelinating polyneuropathy (CIDP) Understanding

Chronic inflammatory demyelinating polyneuropathy (CIDP): Overview

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder which is characterized by inflammation of nerve roots and peripheral nerves in conjunction with destruction of myelin sheath of the nerve fibers. Loss or damage of myelin sheath can slowdown or block the nerve signals. CIDP is an auto-immune disorder with a very low prevalence of around 5-7 cases per 100,000 individuals. Males are more likely to get affected by CIDP as compared to females. At times, diagnosing CIDP can be very difficult. However, muscle weakness for more than two months along

with symmetric proximal and distal weakness with reduced or absent tendon reflexes are highly suggestive of CIDP. There are various effective treatments available for CIDP which primarily consist of glucocorticoids (steroids) like prednisone, some immunosuppressive drugs, intravenous immunoglobulin, and plasma exchange.

“Chronic inflammatory demyelinating polyneuropathy (CIDP) - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline landscape is provided which includes the disease overview and Chronic inflammatory demyelinating polyneuropathy (CIDP) treatment guidelines. The assessment part of the report embraces, in depth Chronic inflammatory demyelinating polyneuropathy (CIDP) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic inflammatory demyelinating polyneuropathy (CIDP) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## **Report Highlights**

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic inflammatory demyelinating polyneuropathy (CIDP) R&D. The therapies under development are focused on novel approaches to treat/improve Chronic inflammatory demyelinating polyneuropathy (CIDP).

### **Chronic inflammatory demyelinating polyneuropathy (CIDP) Emerging Drugs Chapters**

This segment of the Chronic inflammatory demyelinating polyneuropathy (CIDP) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

### **Chronic inflammatory demyelinating polyneuropathy (CIDP) Emerging Drugs**

#### **HYQVIA: Takeda Pharmaceuticals**

Takeda's lead drug candidate, HYQVIA, is a solution for subcutaneous administration.

The drug is being developed for chronic inflammatory demyelinating polyneuropathy disorder. The drug has demonstrated good efficacy and tolerability. It has also been designated with orphan drug status for CIPD. It act as an immunomodulant that reacts with the receptor of targeted cells to up-regulate or down-regulate immune response.

Rozanolixizumab: UCB Biopharma

UCB Biopharma's "novel" drug molecule Rozanolixizumab is currently being evaluated for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). The drug is a neonatal Fc receptor antagonist which belong to the class of anti-inflammatories as well as monoclonal antibodies. Rozanolixizumab works by binding with high-affinity to human neonatal Fc receptor (FcRn), selectively inhibiting IgG rescue and recycling.

Further product details are provided in the report.....

Chronic inflammatory demyelinating polyneuropathy (CIDP): Therapeutic Assessment

This segment of the report provides insights about the different Chronic inflammatory demyelinating polyneuropathy (CIDP) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic inflammatory demyelinating polyneuropathy (CIDP)

There are approx. 10+ key companies which are developing the therapies for Chronic inflammatory demyelinating polyneuropathy (CIDP). The companies which have their Chronic inflammatory demyelinating polyneuropathy (CIDP) drug candidates in the most advanced stage, i.e. phase III include, Takeda Pharmaceuticals.

## **Phases**

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

## **Route of Administration**

Chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

## **Product Type**

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

## Chronic inflammatory demyelinating polyneuropathy (CIDP): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic inflammatory demyelinating polyneuropathy (CIDP) therapeutic drugs key players involved in developing key drugs.

### **Pipeline Development Activities**

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic inflammatory demyelinating polyneuropathy (CIDP) drugs.

## Chronic inflammatory demyelinating polyneuropathy (CIDP) Report Insights

Chronic inflammatory demyelinating polyneuropathy (CIDP) Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## Chronic inflammatory demyelinating polyneuropathy (CIDP) Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Treatment Scenario and Emerging Therapies:

How many companies are developing Chronic inflammatory demyelinating polyneuropathy (CIDP) drugs?

How many Chronic inflammatory demyelinating polyneuropathy (CIDP) drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic inflammatory demyelinating polyneuropathy (CIDP)?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic inflammatory demyelinating polyneuropathy (CIDP) therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Chronic inflammatory demyelinating polyneuropathy (CIDP) and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Takeda Pharmaceuticals

UCB Biopharma

LFB Biotechnologies

Argenx

Octapharma

## Key Products

HYQVIA

Rozanolixizumab

I10E

Efgartigimod

NewGam

## Contents

Introduction

Executive Summary

Chronic inflammatory demyelinating polyneuropathy (CIDP): Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Chronic inflammatory demyelinating polyneuropathy (CIDP) – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Chronic inflammatory demyelinating polyneuropathy (CIDP) companies' collaborations, Licensing, Acquisition -Deal Value Trends

Chronic inflammatory demyelinating polyneuropathy (CIDP) Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

HYQVIA: Takeda Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Rozanolixizumab: UCB Biopharma

Product Description

Research and Development



Product Development Activities  
Drug profiles in the detailed report.....  
Inactive Products  
Comparative Analysis  
Chronic inflammatory demyelinating polyneuropathy (CIDP) Key Companies  
Chronic inflammatory demyelinating polyneuropathy (CIDP) Key Products  
Chronic inflammatory demyelinating polyneuropathy (CIDP)- Unmet Needs  
Chronic inflammatory demyelinating polyneuropathy (CIDP)- Market Drivers and Barriers  
Chronic inflammatory demyelinating polyneuropathy (CIDP)- Future Perspectives and Conclusion  
Chronic inflammatory demyelinating polyneuropathy (CIDP) Analyst Views  
Chronic inflammatory demyelinating polyneuropathy (CIDP) Key Companies  
Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Chronic inflammatory demyelinating polyneuropathy (CIDP)

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Chronic inflammatory demyelinating polyneuropathy (CIDP)

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Chronic inflammatory demyelinating polyneuropathy (CIDP) - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/C77D069696CEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C77D069696CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970